摘要
目的研究miR-19b在儿童急性淋巴细胞白血病(ALL)中的表达及其与ALL临床特征和PTEN mRNA表达的相关性。方法采用实时定量PCR的方法检测67例儿童ALL(初诊组38例、完全缓解组20例、难治复发组9例)骨髓单个核细胞(BMMNC)中miR-19b的表达,分析其表达与临床特征及PTEN mRNA表达水平的关系。以15例原发性免疫性血小板减少症(ITP)患儿作为对照组。结果 miR-19b在初诊组和难治复发组的表达量显著高于完全缓解组和对照组(P<0.01)。动态观察6例ALL患儿发现完全缓解后miR-19b表达量较初诊时显著降低(P<0.05)。miR-19b高表达与外周血高WBC计数(≥50×109/L)、危险度分型(中、高危)、脾肿大、BCR-ABL融合基因阳性有相关性(P<0.05),与发病年龄、性别、免疫分型、形态学分型、MLL-AF4融合基因、肝及淋巴结肿大、早期泼尼松反应等因素无相关性(P>0.05)。miR-19b与PTEN mRNA表达量无相关性(r=0.107,P>0.05)。结论 miR-19b可能在儿童ALL发生、发展及不良预后中发挥一定作用,未发现miR-19b表达量同PTEN mRNA的表达量存在相关性。
Objective To investigate the expression and clinical significance of miR-19b in children with acute lymphoblastic leukemia(ALL),and its relationship with PTEN mRNA.Methods The expression levels of miR-19b in 67 patients with ALL(including 38 newly diagnosed ALL,20 ALL in complete remission(CR) and 9 relapsed/refractory ALL) and 15 children with idiopathic thrombocytopenic purpura(ITP)(as normal controls) were assayed by qRT-PCR.Its relativity with clinical characters and PTEN mRNA was analyzed.Results The expressions of miR-19b in the newly diagnosed group and relapsed/refractory group were higher than those in CR and control groups(P0.01).By sequential observation of miR-19b expression in different stages of ALL in 6 cases,miR-19b expression in CR stage was significantly lower than that in newly diagnosed stage(P0.05).The increased level of miR-19b had a positive correlation with high white blood cell(WBC)(≥50×109/L),risk classification(intermedium-risk and the high-risk group),splenomegaly and BCR-ABL positive(P0.05).miR-19b was not associated with age,gender,FAB phenotype,immunophenotype,hepatomegaly,lymphadenectasis and the response to prednisone(P0.05).There was no correllation between miR-19b and the expression of PTEN mRNA(r=0.107,P0.05).Conclusion miR-19b might play an important role in the pathogenesis and poor prognosis of childhood ALL.As an oncogene the regulation of miR-19b to PTEN mRNA was not detected in ALL boon marrow cells.
出处
《重庆医学》
CAS
CSCD
北大核心
2012年第33期3501-3503,共3页
Chongqing medicine
基金
国家十一五科技掌握计划资助项目(2007BAI04B03)